Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results

Journal of Nuclear Medicine

Volumn 58, Issue 1, 2017, Pages 75-80

  Nock, Berthold A ^a   Kaloudi, Aikaterini ^a   Lymperis, Emmanouil ^a   Giarika, Athina ^a   Kulkarni, Harshad R ^b   Klette, Ingo ^b   Singh, Aviral ^b   Krenning, Eric P ^c   De Jong, Marion ^c   Maina, Theodosia ^a   Baum, Richard P ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET CT) Zentralklinik Bad Berka   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gastrin releasing peptide receptor antagonist; Molecular Tumor Imaging; PET; Prostate cancer; Radionuclide therapy; SPECT; Theranostic applications

Indexed keywords

DIPEPTIDE; GALLIUM 67; GALLIUM 68; GALLIUM DOTATATE GA 68; GASTRIN RELEASING PEPTIDE RECEPTOR; INDIUM 111; LEUCINE; LEUCINE 13; LUTETIUM 177; METHIONINE; METHIONINE 14; RADIOLIGAND; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD ANALYSIS; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CHEMICAL STRUCTURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; KIDNEY; MALE; METABOLIC STABILITY; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; THERANOSTIC NANOMEDICINE; X-RAY COMPUTED TOMOGRAPHY; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; PILOT STUDY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION RESPONSE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; PILOT PROJECTS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 85009121641     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.178889     Document Type: Review

References (39)

1. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
2. Körner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217-224.
3. Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318-325.
4. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
5. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-862.
6. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55:280-287.
7. Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging. 2006;6:153-157.
8. Yu Z, Ananias HJ, Carlucci G, et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des. 2013;19:3329-3341.
9. Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-2024.
10. Nock BA, Nikolopoulou A, Galanis A, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: A preclinical study. J Med Chem. 2005;48:100-110.
11. Zhang H, Schuhmacher J, Waser B, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198-1208.
12. Breeman WA, De Jong M, Bernard BF, et al. Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657-663.
13. Nock BA, Cescato R, Ketani E, Waser B, Reubi JC, Maina T. [99mTc]demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing Peptide receptor-expressing models. J Med Chem. 2012;55:8364-8374.
14. Marsouvanidis PJ, Maina T, Sallegger W, Krenning EP, de Jong M, Nock BA. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation. J Nucl Med. 2013;54:1797-1803.
15. Marsouvanidis PJ, Maina T, Sallegger W, Krenning EP, de Jong M, Nock BA. Tumor diagnosis with new 111In-radioligands based on truncated human gastrin releasing peptide sequences: synthesis and preclinical comparison. J Med Chem. 2013;56:8579-8587.
16. Bodei L, Ferrari M, Nunn A, et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: A phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221.
17. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
18. Nock B, Nikolopoulou A, Chiotellis E, et al. [99mTc]demobesin 1, a novel potent bombesin analogue for GRP receptor-Targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:247-258.
19. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist: from mice to men. Theranostics. 2014;4:412-419.
20. Mansi R, Abiraj K, Wang X, et al. Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors. J Med Chem. 2015;58:682-691.
21. Marsouvanidis PJ, Nock BA, Hajjaj B, et al. Gastrin releasing peptide receptordirected radioligands based on a bombesin antagonist: synthesis, 111In-labeling, and preclinical profile. J Med Chem. 2013;56:2374-2384.
22. Chatalic KL, Konijnenberg M, Nonnekens J, et al. In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies. Theranostics. 2016;6: 104-117.
23. Maina T, Bergsma H, Kulkarni HR, et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-Antagonist [68Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:964-973.
24. Lymperis E, Maina T, Kaloudi A, Krenning EP, de Jong M, Nock BA. Transient in vivo NEP inhibition enhances the theranostic potential of the new GRPRantagonist [111In/177Lu]SB. Eur J Nucl Med Mol Imaging. 2014;41(suppl 2): S319.
25. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
26. Heimbrook DC, Saari WS, Balishin NL, et al. Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991;34:2102-2107.
27. Reile H, Armatis PE, Schally AV. Characterization of high-Affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-[Tyr4]bombesin by tumor cells. Prostate. 1994;25:29-38.
28. Dalm SU, Bakker I, de Blois E, et al. NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use. J Nucl Med. September 8, 2016 [Epub ahead of print].
29. Oberg K. Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics. 2012;2:448-458.
30. Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42: 190-207.
31. Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012;2:481-501.
32. de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42:873-880.
33. Maina T, Nock BA, Zhang H, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-Targeting drugs. J Nucl Med. 2005;46:823-830.
34. de Jong M, Maina T. Of mice and humans: Are they the same?-Implications in cancer translational research. J Nucl Med. 2010;51:501-504.
35. Bakker IL, Fröberg A, Busstra M, et al. A novel gallium-68-labelled GRP receptor antagonist, [68Ga]sarabesin 3, for prostate cancer imaging: first results in therapy naïve primary patients. Eur J Nucl Med Mol Imaging. 2015;42(suppl 1): S125.
36. Bakker IL, Fröberg A, Busstra M, et al. PET imaging of therapy-naïve primary prostate cancer patients using the GRPr-Targeting ligand sarabesin 3 [abstract]. Eur Urol Suppl. 2016;15:567.
37. Mather SJ, Nock BA, Maina T, et al. GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: A first-in-man study. Mol Imaging Biol. 2014;16:888-895.
38. Ristau BT, OKeefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32:272-279.
39. Minamimoto R, Hancock S, Schneider B, et al. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57:557-562.